GlassScriptPhysician profile
Janell M Rubelt
NPI 1396307443
$1,311.16
in general payments reported to CMS, 2019-2025
18 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $89.00 · 2022: $226 · 2023: $201 · 2024: $501 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $202.77 | 2024-2025 | Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $192.61 | 2024-2025 | Uzedy, Austedo Xr |
| Aerin Medical INC. | $166.30 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.90 | 2024-2025 | Caplyta |
| Advanced Bionics, LLC | $98.14 | 2022 | |
| Alkermes, INC. | $92.39 | 2024-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $77.77 | 2024-2025 | Auvelity |
| Csl Behring | $72.52 | 2021-2023 | Hizentra |
| Genzyme Corporation | $66.77 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $58.73 | 2025 | Cobenfy |
| Janssen Scientific Affairs, LLC | $36.06 | 2025 | Invega Sustenna |
| Regeneron Healthcare Solutions, INC. | $35.15 | 2023 | Dupixent |
| Organogenesis INC. | $25.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.30 | 2022 | |
| Stryker Corporation | $19.60 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $15.14 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $14.52 | 2025 | |
| Glaxosmithkline, LLC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janell Rubelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.